ID   Ff-XT28s05-ABo_To #14-3
AC   CVCL_C1FQ
DR   Wikidata; Q114311431
RX   Patent=US20200407693;
RX   PubMed=30853558;
CC   From: Center for iPS Cell Research and Application, Kyoto University; Kyoto; Japan.
CC   Population: Japanese.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:7067; CIITA.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:4931; HLA-A.
CC   Knockout cell: Method=CRISPR/Cas9; HGNC; HGNC:4932; HLA-B.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_C1FP ! Ff-XT28s05-ABo #14
SX   Male
AG   Age unspecified
CA   Induced pluripotent stem cell
DT   Created: 22-09-22; Last updated: 19-12-24; Version: 6
//
RX   Patent=US20200407693;
RA   Hotta A., Xu H.-G., Kaneko S., Wang B.;
RT   "Method for producing low-antigenic cell.";
RL   Patent number US20200407693, 31-Dec-2020.
//
RX   PubMed=30853558; DOI=10.1016/j.stem.2019.02.005;
RA   Xu H.-G., Wang B., Ono M., Kagita A., Fujii K., Sasakawa N., Ueda T.,
RA   Gee P., Nishikawa M., Nomura M., Kitaoka F., Takahashi T., Okita K.,
RA   Yoshida Y., Kaneko S., Hotta A.;
RT   "Targeted disruption of HLA genes via CRISPR-Cas9 generates iPSCs with
RT   enhanced immune compatibility.";
RL   Cell Stem Cell 24:566-578.e7(2019).
//